You are here
Immunotherapy: KEYNOTE-028 trial
In this session, the speakers discuss the reasons for failure of immunotherapy in prostate cancer. The speakers also analyze the overall response rate in the KEYNOTE trial with pembrolizumab monotherapy. They refer to interesting observations in this study such as none of the patients died or discontinued pembrolizumab due to treatment-related adverse events and the demonstration of anti-tumour activity and favourable safety profile.